CURRICULUM VITAE

PERSONAL INFORMATION

Name Pietro Ameri July 31st, 1981

Nationality Italian

Work address

(clinical) Padiglione Monoblocco, settimo piano lato levante

IRCCS Ospedale Policlinico San Martino

Largo Rosanna Benzi 10 – 16132 Genova, Italy

(office) Dipartimento di Medicina Interna e Specialità Mediche

Università degli Studi di Genova

Viale Benedetto XV, 6 - 16132 Genova, Italy

Phone +39 010 3538928 E-mail pietroameri@unige.it



CURRENT POSITIONS

Since 2020 Associate Professor in Cardiology, Department of Internal Medicine, University of Genova,

Genova, Italy

Since 2015 Staff Cardiologist and Coordinator of the Heart Failure and Pulmonary Hypertension

Programs at the Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino,

Genova, Italy

Since 2014 Head of the Laboratory of Cardiovascular Biology, IRCCS Ospedale Policlinico San Martino

& Department of Internal Medicine, University of Genova, Genova, Italy

PREVIOUS POSITIONS

2014 - 2020 Assistant Professor in Cardiology, Department of Internal Medicine, University of Genova 2012 - 2013 Research Scientist at the Bunnie Joan Sachs Laboratory, Department of Medicine, New

York University School of Medicine, New York, NY, U.S.A.

2009 - 2010 Visiting researcher at the Bunnie Joan Sachs Laboratory, New York University School of

Medicine, New York, NY, U.S.A.

EDUCATION

2012 - 2014 Ph.D. in Cardiovascular, Renal, and Metabolic Biology and Pathophysiology

School of Clinical and Experimental Internal Medicine, University of Genova, Genova, Italy

2007 - 2012 Residency in Internal Medicine, University of Genova, Genova, Italy

2000 - 2006 School of Medicine, University of Genova, Genova, Italy

MEDICAL LICENSES

2010 United States Medical Licensing Examination (USMLE) Step 1, scores 236 and 99 and

Step 2 Clinical Knowledge, scores 242 and 99

2007 Italian Medical License, score 270/270

SCIENTIFIC ACTIVITY

H-index 37 (Scopus).

Select original research articles

- Toma M, Savonitto G, Lombardi CM, [...], Giudice FL, Stolfo D, Ameri P. Frequency, characteristics and risk assessment of pulmonary arterial hypertension with a left heart disease phenotype. <u>Clin Res Cardiol</u>. 2024 Apr 15. doi: 10.1007/s00392-024-02448-9
- Schnabel RB*, Ameri P*, Siller-Matula JM, Diemberger I, Gwechenberger M, Pecen L, Manu MC, Souza J, De Caterina R, Kirchhof P. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry. <u>Europace</u>. 2023;25:euad280 (* equal contribution)
- De Marzo V, Savarese G, Tricarico L, Hassan S, Iacoviello M, Porto I, Ameri P. Network meta-analysis of medical therapy efficacy in more than 90000 patients with heart failure and reduced ejection fraction. <u>J</u> <u>Intern Med</u>. 2022;292:333-49
- Toma M, Miceli R, Bonsante E, Colombo D, Confalonieri M, Garascia A, Ghio S, Lattanzio M, Lombardi CM, Paciocco G, Piccinino C, Rota I, Santolamazza C, Scelsi L, Scuri P, Stolfo D, Vincenzi A, Volpiano L, Vicenzi M, Ameri P. Left Heart Disease Phenotype in Elderly Patients with Pulmonary Arterial Hypertension: Insights from the Italian PATRIARCA Registry. J Clin Med. 2022;11:7136
- Bertero E, Robusto F, Rulli E, D'Ettorre A, Bisceglia L, Staszewsky L, Maack C, Lepore V, Latini R, Ameri P. Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort. JACC Cardio-Oncology, 2022;4:98-109
- o **Ameri P**, De Marzo V, Zoccai GB, Tricarico L, Correale M, Brunetti ND, Canepa M, De Ferrari GM, Castagno D, Porto I. *Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2022;8:768-76*
- Tini G, Bertero E, Signori A, Sormani MP, Maack C, De Boer RA, Canepa M, Ameri P. Cancer mortality in trials of heart failure with reduced ejection fraction: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9:e016309.
- o Toma M, Rrapaj E, Spallarossa P, Guerra F, **Ameri P**. Patterns of anticoagulation for atrial fibrillation in cancer patients referred to cardio-oncological evaluation. <u>Eur J Intern Med</u>. 2020:S0953-6205(20)30319-8
- Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, Di Bona A, Margaria JP, Martini M, Lazzarini E, Pirozzi F, Rossi L, Franco I, Bornbaum J, Heger J, Rohrbach S, Perino A, Tocchetti CG, Lima BHF, Teixeira MM, Porporato PE, Schulz R, Angelini A, Sandri M, Ameri P, Sciarretta S, Lima-Júnior RCP, Mongillo M, Zaglia T, Morello F, Novelli F, Hirsch E, Ghigo A. *Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth*. Circulation. 2018;138:696-711
- Altieri P, Bertolotto M, Fabbi P, Sportelli E, Balbi M, Santini F, Brunelli C, Canepa M, Montecucco F, Ameri P. Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects. Int J Cardiol. 2018;271:219-27
- Altieri P, Murialdo R, Barisione C, Lazzarini E, Garibaldi S, Fabbi P, Ruggeri C, Borile S, Carbone F, Armirotti A, Canepa M, Ballestrero A, Brunelli C, Montecucco F, Ameri P*, Spallarossa A. 5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. Br J Pharmacol. 2017;174:3713-26 (* corresponding author)
- Altieri P, Barisione C, Lazzarini E, Garuti A, Bezante GP, Canepa M, Spallarossa P, Tocchetti CG, Bollini S, Brunelli C, Ameri P. Testosterone antagonizes doxorubicin-induced senescence of cardiomyocytes. <u>J Am Heart Assoc</u>. 2016;5:e002383

Select review articles / scientific documents

- Ameri P, Mercurio V, Pollesello P, [...], Rosano G, Rosenkranz S, Tocchetti CG. A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function. <u>Eur J Heart Fail</u>. 2024;26:707-29
- o Ameri P, Bertero E, Lombardi M, Porto I, Canepa M, Nohria A, Vergallo R, Lyon AR, López-Fernández T.

- Ischemic heart disease in patients with cancer. Eur Heart J. 2024;45:1209-23
- Ameri P, Bertero E, Maack C, Teerlink JR, Rosano G, Metra M. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? <u>Eur Heart J Cardiovasc Pharmacother</u>. 2021;7:539-46
- Tocchetti CG, Ameri P*, de Boer RA, D'Alessandra Y, Russo M, Sorriento D, Ciccarelli M, Kiss B, Bertrand L, Dawson D, Falcao-Pires I, Giacca M, Hamdani N, Linke WA, Mayr M, van der Velden J, Zacchigna S, Ghigo A, Hirsch E, Lyon AR, Görbe A, Ferdinandy P, Madonna R, Heymans S, Thum T. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovasc Res. 2020;116:1820-34 (* equal contribution)
- Spallarossa P, Tini G, Sarocchi M, Arboscello E, Grossi F, Queirolo P, Zoppoli G, Ameri P. Identification and management of immune checkpoint inhibitor-related myocarditis: use troponin wisely. <u>J Clin Oncol</u>. 2019;37:2201-05
- Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, Farmakis D, López-Fernández T, Lainscak M, Pudil R, Ruschitska F, Seferovic P, Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon AR, Tocchetti CG; Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail. 2018;20:879-87
- Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer: background evidence and research perspectives. Circulation. 2018;138:735-42
- Bertero E, Prates Roma L, Ameri P, Maack C. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
 Cardiovasc Res. 2018;114:12-8
- Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P, Agnetti G, Tocchetti CG, Ghigo A, Ameri P. Models of heart failure based on the cardiotoxicity of anticancer drugs. <u>J Card Fail</u>. 2016;S1071-9164:30023-9

COMPETITIVE FUNDING

<u>2023:</u> PRIN 2022 PNRR grant n. P20225BYWX from the Italian Ministry of University and Research for the research project "A translational stuDy to dISseCt remOdeling of capillaries and Veins in pulmonary hypErtension associated with heaRt failure (DISCOVER PH-HF)" (co-investigator)

<u>2022:</u> PNRR2022 grant n. PNRR-MAD-2022-12376632 from the Italian Ministry of Health for the research project "New molecular targets for the prevention of anthracycline-induced cardiotoxicity: a translational study" (coinvestigator)

<u>2021:</u> 5x1000 grant from IRCCS Ospedale Policlinico San Martino for the research project: "Role of AgRP neurons in acute myocardial infarction and ischemic stroke (PREMIER study)" (principal investigator)

<u>2019</u>: "Progetto Giovani Ricercatori 2018" grant n. GR-2018-12365661 from the Italian Ministry of Health for the research project: "Cancer in Heart fAilure: characteriziNg the association with a dual epidemioloGical and Experimental approach (CHANGE study)" (principal investigator)

<u>2019</u>: Young Investigator Grant from the Department of Internal Medicine, University of Genova (principal investigator)

<u>2015:</u> Investigator-initiated grant from Boehringer Ingelheim for the research project "Study of the effects of free or dabigatran-inhibited thrombin on human atrial fibroblasts: implications for atrial fibrillation-related myocardial remodeling" (principal investigator)

<u>2014</u>: "Progetto Giovani Ricercatori 2013" grant from the Italian Ministry of Health for the research project "The Stem cell sEcretome for doxorubicin-induced Cardiomyopathy REgeneraTion (SECRET)" (co-investigator)

<u>2014</u>: "Progetto di Ricerca d'Ateneo 2014" grant from the University of Genova for the study "IGF-1 in anthracycline cardiotoxicity: implications for treatment of breast cancer" (principal investigator).

Non-competitive funding for research support from the Italian Ministry of Health and the University of Genova.

PARTICIPATION IN INTERNATIONAL CLINICAL STUDIES

Local Principal Investigator of several international multicenter studies, including:

- "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)" (PROSERA) (EudraCT: 2023-503614-80-00)
- "A Phase 2b Randomised, Double-blind, Placebo controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)" (Re-PHIRE)
- "A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension (ELEVATE 2)" (EudraCT: (2020-004971-42)
- "ROR-PH-301 A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH)-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH (ADVANCE Outcomes)" (EudraCT 2018-001189-40)
- "A Multicenter, Double-blind, Placebo controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)" (EudraCT: 2018-005030-38)
- "A randomised, double-blind placebo controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron deficient patients admitted for acute heart failure -AFFIRM AHF" (EudraCT: 2016-001467-36)
- Non-interventional Study on Patients With Atrial Fibrillation and Cancer (BLITZ-AF Cancer, NCT03909386)

PARTICIPATION IN SCIENTIFIC SOCIETIES

Fellow of the Heart failure Association (HFA) of the European Society of Cardiology (ESC)

2024-2026: Secretary of the ESC Council of Cardio-Oncology

2024-2026: Member of the HFA Scientific Committee on Basic & Translational Research

Member of the Study Group on Cardio-Oncology (2022-2024), the Winter Meeting Committee (2022-2024),

the Committee on Translational Research (2020-2022), and the Study Group on Cardio-Oncology (2020-2022) of the HFA

Member of the Board of Directors and Chair of the Cardio-Oncology Committee of the IRCCS Italian

Cardiology Network (network of Italian research hospitals: https://retecardiologica.it/en)

Member of: ESC; ESC Working Group on Myocardial Function; International Society for Heart Research; Italian Society of Cardiology; Italian Society of Cardiovascular Prevention; Italian Society of Cardiovascular Research

OTHER SCIENTIFIC ACTIVITIES

Local host Italy of the ESC Cardio-Oncology 2025 Annual Conference

Editor of Journal of Thrombosis and Thrombolysis and Journal of Cardiovascular Medicine, Associate Editor of Journal of Cellular and Molecular Medicine (current); Cardio-oncology Section Editor of Current Heart Failure Reports (2019-2022)

Reviewer of grant applications for the Israel Science Foundation, the Swiss National Science Foundation, the Swiss Cancer Research Foundation, and the Czech Science Foundation.

Reviewer for Nature Medicine and major cardiovascular journals, including European Heart Journal, Circulation, European Journal of Heart Failure, and Cardiovascular Research.

Pietro Ameri, M.D., Ph.D.

TEACHING ACTIVITY

Coordinator of the Translational and Clinical Internal Medicine PhD Program of the University of Genova (tacim.phd.unige.it)

Professor of Cardiovascular Medicine at the University of Genova (School of Medicine, PhD Program in Clinical and Internal Medicine, and Residency Programs)

As of September 20th, 2024